Contineum Therapeutics Operating Income

Contineum Therapeutics (CTNM) currently reports a operating income of $-66M as of June 2026. That compares with $-66M in the prior-year period — down 0.5% year over year. Use the charts on this page to explore Contineum Therapeutics's operating income history and peer comparisons.

Contineum Therapeutics's operating income decreased from $-66M to $-66M — a 0.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Contineum Therapeutics reported $-66M in operating income as of June 2026. That compares with $-66M in the prior-year period — down 0.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-66M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Contineum Therapeutics, and consider following CTNM for alerts when major investors trade the stock.